South African health authorities are moving to tighten regulations governing pharmacies that produce their own compound versions of high-demand medications, including popular diabetes and weight-loss treatments such as Ozempic and Mounjaro. The planned regulatory shift aims to address growing concerns that certain retail pharmacies have expanded past traditional compounding into operating effectively as small-scale manufacturers, producing substantial quantities of medications in advance rather than compounding individual prescriptions for specific patients.
Vincent Tlala, CEO of the South African Pharmacy Council, stated that his organization is collaborating closely with the industry regulator to update the standards that govern the compounding of medicines. The new guidelines are anticipated to be published around March of next year.
The initiative is expected to draw support from major international pharmaceutical companies, including Novo Nordisk and Eli Lilly, which have sought to limit the availability of pharmacy-compounded alternatives competing directly with their trademarked GLP-1 blockbuster treatments. Demand for these therapies is particularly high in South Africa, which maintains the highest adult obesity rate on the African continent at 30 percent. However, the high cost of the brand-name trademarked medications places them beyond the financial reach of the majority of the population.
The upcoming regulatory discussions follow a legal victory secured by Novo Nordisk in June against local compounding pharmacies that were producing unauthorized copies of its treatments. As the regulatory framework evolves, authorities aim to draw a sharper legal distinction between customized patient compounding and unauthorized bulk production.
